OR WAIT null SECS
September 09, 2020
The company is investing $130 million to add Phase III through commercial-scale manufacturing suites to its gene therapy campus in Harmans, MD.
September 03, 2020
Rapid scale-up to billions of doses requires collaborative, all-out efforts by innovators, their manufacturing partners, and the entire supply chain.
August 24, 2020
Catalent will manufacture drug substance for AZD1222 at its Harmans, MD facility.
August 21, 2020
CDMO Avid Bioservices will provide development and drug substance manufacturing for Oragenics’ novel COVID-19 vaccine candidate, Terra CoV-2.
August 13, 2020
The company has made several moves in recent weeks to expand manufacturing capacity and cell line services.
August 02, 2020
The early success seen on the market for approved cell and gene therapies poses both technical and manufacturing challenges for pipeline candidates on the road to commercialization.
July 21, 2020
Catalent has unveiled plans to invest in a European center of excellence for clinical biologics formulation development and drug product fill/finish services at its facility in Limoges, France.
July 02, 2020
The COVID-19 pandemic has created a rise in demand for R&D and a shift in focus for some contract organizations.
June 17, 2020
Cobra Biologics has signed a supply agreement to provide GMP manufacturing for AstraZeneca’s AZD1222 COVID-19 vaccine candidate.
June 01, 2020
The companies have entered into a manufacturing agreement for the fill finish supply of lenzilumab for the potential treatment of COVID-19.